Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilaris for Anemia in Lower-Risk MDS (CANFIRE)
NCT05237713Phase 2Terminated
- Sponsor
- Leipzig University
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in anemia, myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Leipzig University. Started Apr 2022; status: terminated.
02
Drugs
canakinumab
03
Conditions
anemiamyelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT05237713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05237713.